SEC Comment Letter for INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519) — Aug 19, 2022

INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)
Date: Aug. 19, 2022 · CIK: 0001292519 · Accession: 0000000000-22-008906

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-37350

Date

August 19, 2022

Author

Not clearly detected

Form

UPLOAD

Company

INVIVO THERAPEUTICS HOLDINGS CORP. (CIK 0001292519)

Letter

United States securities and exchange commission logo August 19, 2022 Richard Toselli, M.D. President and Chief Executive Officer INVIVO THERAPEUTICS HOLDINGS CORP. One Kendall Square, Suite B14402 Cambridge, MA 02139 Re:INVIVO THERAPEUTICS HOLDINGS CORP. Preliminary Proxy Statement on Schedule 14A Filed July 8, 2022 File No. 001-37350 Dear Dr. Toselli: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary Reilly, Esq.

Show Raw Text

United States securities and exchange commission logo
August 19, 2022
Richard Toselli, M.D.
President and Chief Executive Officer
INVIVO THERAPEUTICS HOLDINGS CORP.
One Kendall Square, Suite B14402
Cambridge, MA 02139
Re:INVIVO THERAPEUTICS HOLDINGS CORP.
Preliminary Proxy Statement on Schedule 14A
Filed July 8, 2022
File No. 001-37350
Dear Dr. Toselli:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Rosemary Reilly, Esq.

SecProbe.io